Korro Bio vs Vistagen Therapeutics
Korro Bio is the larger business, with $6.4m of revenue in fiscal 2025 against $1.3m for Vistagen Therapeutics (5.0 times as much). Korro Bio grew faster (181.5% against 161.1%). Korro Bio kept more of each dollar of sales as profit: a net margin of -1834.5% against -5491.3%.
| Latest fiscal year | Korro BioKRRO, 2025 | Vistagen TherapeuticsVTGN, 2026 |
|---|---|---|
| Revenue | $6.4m | $1.3m |
| Revenue growth | 181.5% | 161.1% |
| Net income | −$117m | −$69.7m |
| Operating margin | — | — |
| Net margin | -1834.5% | -5491.3% |
| Return on equity | -110.7% | -131.6% |
| Free cash flow | −$79.1m | −$66.4m |
| Cash | $21.8m | $30.8m |
| Total debt | $0 | $96,000 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 58 | 41 |
| Market value | $235m | $7.3m |
| Price vs our value range | — | — |
| Moat score | — | 10 (Weak) |
| Insider trades, 12 months | 16 buys, 33 sales | 0 buys, 0 sales |